Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma

Adenocarcinoma Pancreas Clinical Trial

Official title:
Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients With Pancreatic Adenocarcinoma

Status Completed

Clinical Trial Summary

This study will use PET/MRI in patients with adenocarcinoma of the pancreas to identify hidden metastatic disease or identify patients with borderline or locally advanced disease.

Clinical Trial Description

Patients will receive a PET/MRI scan within 6 weeks of their standard of care imaging. There is no maximum number of scans for research. The number of scans depends on each patient's treatment plan. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02028377
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Completed
Phase	N/A
Start date	February 2013
Completion date	August 22, 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01315548` - Contrast Enhanced Harmonic Endoscopic Ultrasound (CEH-EUS) in Focal Pancreatic Masses	N/A
Completed	`NCT02812992` - Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients	Phase 4
Terminated	`NCT01783054` - Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas	Phase 0
Completed	`NCT01456585` - Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma	Phase 1